AMYLYX PHARMACEUTICALS INC's ticker is and the CUSIP is 03237H101. A total of 102 filers reported holding AMYLYX PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.57 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,431,585 | -43.4% | 78,186 | -33.3% | 0.00% | – |
| Q2 2023 | $2,528,241 | +26.1% | 117,211 | +71.6% | 0.00% | – |
| Q1 2023 | $2,004,625 | -14.4% | 68,324 | +7.8% | 0.00% | – |
| Q4 2022 | $2,341,374 | +832.8% | 63,366 | +613.0% | 0.00% | – |
| Q3 2022 | $251,000 | -21.3% | 8,887 | -46.4% | 0.00% | – |
| Q2 2022 | $319,000 | +739.5% | 16,570 | +470.6% | 0.00% | – |
| Q1 2022 | $38,000 | – | 2,904 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 2,515,868 | $46,065,543 | 15.30% |
| Alpha Wave Global, LP | 853,262 | $15,623,227 | 9.88% |
| Saturn V Capital Management LP | 886,143 | $16,225,278 | 6.79% |
| Ally Bridge Group (NY) LLC | 272,690 | $4,992,954 | 5.86% |
| Altium Capital Management LP | 534,700 | $9,790,357 | 5.11% |
| Boxer Capital, LLC | 2,084,000 | $38,158,040 | 2.03% |
| Octagon Capital Advisors LP | 695,000 | $12,725,450 | 1.96% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 295,000 | $5,398,500 | 1.82% |
| Tri Locum Partners LP | 282,862 | $5,179,203 | 1.66% |
| Perceptive Advisors | 2,688,873 | $49,233,265 | 1.64% |